DAX-0,72 % EUR/USD-0,04 % Gold-0,40 % Öl (Brent)-0,62 %

MIMEDX 5 DAY DEADLINE ALERT Approximately 5 Days Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against MiMedx Group Inc. - MDXG

Nachrichtenquelle: Business Wire (engl.)
21.04.2018, 04:50  |  367   |   |   

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until April 25, 2018 to file lead plaintiff applications in a securities class action lawsuits against MiMedx Group Inc. (NasdaqCM: MDXG). Investor losses must relate to purchases of the Company’s securities between the expanded period of March 7, 2013 and February 21, 2018. These actions are pending in the United States District Courts for the Northern District of Georgia and Southern District of New York.

What You May Do

If you purchased securities of MiMedx and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-mdxg/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by April 25, 2018.

About Kahn Swick & Foti, LLC

KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Wertpapier
MiMedx Group
Mehr zum Thema
K+SLew


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Weitere Nachrichten des Autors

Titel
Titel
Titel
Titel